- Home
- FIGR vs BIO Comparison
FIGR vs BIO Comparison
Compare FIGR & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FIGR
- BIO
- Stock Information
- Founded
- FIGR 2018
- BIO 1952
- Country
- FIGR United States
- BIO United States
- Employees
- FIGR N/A
- BIO N/A
- Industry
- FIGR Finance: Consumer Services
- BIO Biotechnology: Laboratory Analytical Instruments
- Sector
- FIGR Finance
- BIO Industrials
- Exchange
- FIGR Nasdaq
- BIO Nasdaq
- Market Cap
- FIGR 6.9B
- BIO 7.7B
- IPO Year
- FIGR 2025
- BIO N/A
- Fundamental
- Price
- FIGR N/A
- BIO $280.09
- Analyst Decision
- FIGR
- BIO Strong Buy
- Analyst Count
- FIGR 0
- BIO 4
- Target Price
- FIGR N/A
- BIO $333.50
- AVG Volume (30 Days)
- FIGR 25.1M
- BIO 229.8K
- Earning Date
- FIGR 01-01-0001
- BIO 10-29-2025
- Dividend Yield
- FIGR N/A
- BIO N/A
- EPS Growth
- FIGR N/A
- BIO N/A
- EPS
- FIGR 1.25
- BIO 11.49
- Revenue
- FIGR $327,242,000.00
- BIO $2,554,200,000.00
- Revenue This Year
- FIGR N/A
- BIO $2.12
- Revenue Next Year
- FIGR N/A
- BIO $2.90
- P/E Ratio
- FIGR $26.00
- BIO $24.39
- Revenue Growth
- FIGR 81.34
- BIO N/A
- 52 Week Low
- FIGR $30.01
- BIO $211.43
- 52 Week High
- FIGR $38.05
- BIO $387.99
- Technical
- Relative Strength Index (RSI)
- FIGR N/A
- BIO 48.12
- Support Level
- FIGR N/A
- BIO $276.52
- Resistance Level
- FIGR N/A
- BIO $298.00
- Average True Range (ATR)
- FIGR 0.00
- BIO 7.65
- MACD
- FIGR 0.00
- BIO -2.84
- Stochastic Oscillator
- FIGR 0.00
- BIO 14.28
About BIO Bio-Rad Laboratories Inc.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.